SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma

Bin Xu; Min-Hua Ye; Shi-Gang Lv; Qi-Xue Wang; Miao-Jing Wu; Bing Xiao; Chun-Sheng Kang; Xin-Gen Zhu

doi:10.18632/oncotarget.16693

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma

Bin Xu, Min-Hua Ye, Shi-Gang Lv, Qi-Xue Wang, Miao-Jing Wu, Bing Xiao, Chun-Sheng Kang and Xin-Gen Zhu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:43953-43966. https://doi.org/10.18632/oncotarget.16693

Metrics: PDF 1530 views | HTML 2611 views | ?

Abstract

Bin Xu1,*, Min-Hua Ye1,*, Shi-Gang Lv1, Qi-Xue Wang2,3, Miao-Jing Wu1, Bing Xiao1, Chun-Sheng Kang2,3 and Xin-Gen Zhu1

1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

2Department of Neurosurgery, Tianjin Medical University General Hospital, Heping District, Tianjin, China

3Laboratory of Neuro-Oncology, Tianjin Neurological Institute, Tianjin, China

*These authors have contributed equally to this work

Correspondence to:

Xin-Gen Zhu, email: [email protected]

Chun-sheng Kang, email: [email protected]

Keywords: SNORD47, glioblastoma, cell cycle, proliferation, invasion

Abbreviations: snoRNAs: small nucleolar RNAs; EMT: epithelial-mesenchymal transition; GAS5: growth arrest-specific transcript 5

Received: February 06, 2017 Accepted: March 03, 2017 Published: March 30, 2017

ABSTRACT

SNORD47 is a member of the C/D box small nucleolar RNAs, which have been implicated in cancer development. We intended to investigate the therapeutic potential of SNORD47 in glioma. We found that the expression of SNORD47 was downregulated in glioma tissues samples and inversely associated with advanced tumor stage (WHO grade IV). Kaplan-Meier survival analysis revealed that glioma patients with high SNORD47 expression had longer overall survival than those with low SNORD47 expression. SNORD47 suppressed the proliferation of glioma cells and induced G2 phase arrest. In addition, upregulation of SNORD47 suppressed invasion and epithelial-mesenchymal transition in glioma cells, and combination treatment with lenti-SNORD47 could augment the anti-tumor effect of temozolomide. These results showed that SNORD47 acted as a tumor suppressor in glioma, and provided the potential anti-tumor function in glioma treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16693

Publication Alerts

Research Papers:

SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma

Abstract